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The alpha-radioactive polonium 210 (Po-210) is one of the most powerful carcinogenic agents of tobacco smoke and is responsible
for the histotype shift of lung cancer from squamous cell type to adenocarcinoma. According to several studies, the principal
source of Po-210 is the fertilizers used in tobacco plants, which are rich in polyphosphates containing radio (Ra-226) and its decay
products, lead 210 (Pb-210) and Po-210. Tobacco leaves accumulate Pb-210 and Po-210 through their trichomes, and Pb-210
decays into Po-210 over time. With the combustion of the cigarette smoke becomes radioactive and Pb-210 and Po-210 reach
the bronchopulmonary apparatus, especially in bifurcations of segmental bronchi. In this place, combined with other agents, it
will manifest its carcinogenic activity, especially in patients with compromised mucous-ciliary clearance. Various studies have
confirmed that the radiological risk from Po-210 in a smoker of 20 cigarettes per day for a year is equivalent to the one deriving
from 300 chest X-rays, with an autonomous oncogenic capability of 4 lung cancers per 10000 smokers. Po-210 can also be found in
passive smoke, since part of Po-210 spreads in the surrounding environment during tobacco combustion. Tobacco manufacturers
have been aware of the alpha-radioactivity presence in tobacco smoke since the sixties.
1. Introduction
WHOhas declared a tobacco epidemic, indicating the spread
of smoking dependency, which aﬀects 1.3 billion people
worldwide and results in 5.4 million tobacco-related deaths
each year. If this trend continues, there will have been
10 million deaths by 2030 [1]. Smoking-related diseases
include lung, esophagus, and pancreas cancer, cardiovascular
diseases, COPD, pneumonia, sudden infant death syndrome,
prematurity, and deaths caused by fires from cigarette stubs
[2]. In Europe 650000 people die each year from smoking-
related diseases.
Every year, approximately 11 million people are diag-
nosed with cancer worldwide; 8 million of them will die [3].
Cancer is a significant public health problem in Europe as
well. In 2000, 1122000 deaths from cancer were registered
in the 25 countries of the European Union (EU). From
1990–1994 to 2000–2004, mortality for all types of cancer
in the EU declined from 185.2 to 168.0 per 100000 (world
standard,−9%) in men and from 104.8 to 96.9 (−8%) in
women [4, 5].
Tobacco smoking is a risk factor for six out of eight main
death causes all over the world; with lung cancer being one
of the six causes, tobacco represents the most important one
[6, 7]. Each year 1.35 million new cases are diagnosed, which
represents more than 12% of all the new cancer cases [8].
Furthermore, smoking is responsible for 1.18 million deaths
from cancer (17.6% of the world total) [9], of which 21400
are lung cancers from second-hand smoking [10]. Survival
rates for all stages and histological types are 10–15% [11].
Almost 46% of new cases of nonsmall-cell lung cancer
pertain to the IIIB and IV stages [12]. In Europe, lung
cancer mortality is 37.6 per 100000 people, ranging from
a maximum in the UK (43.3 per 100000) to a minimum
in Sweden (24.7 per 100000) [13]. In 2008, there were over
32000 new cases of lung cancer in Italy, 25147 of which
2 Journal of Oncology
were men and 6955 women, while deaths reached 26211.
Not so long ago, incidence was higher in men (at a 5 : 1
ratio), but nowadays it has dropped to half (2.5/1 ratio)
[14]. This malignant tumor has become more and more
frequent in women due to their increasing consumption of
tobacco and higher predisposition to its carcinogenic eﬀect.
In fact, trends in incidence and mortality for both sexes have
been completely diﬀerent with declining rates in males and
increasing ones in females. Despite this hecatomb of human
lives, 1.3 billion people in the world and among them 47
million Americans (25%) [15] and 11.1 million Italians over
14 years (21.7% overall; 23.9% males and 19.7% females)
continue smoking [16].
2. The Unrestricted Rise of Lung Cancer
Tobacco smoke has been known to be harmful for health
since the fifties [17, 18]. In 1889, lung cancer was an
extremely rare disease: only 140 cases were registered in the
world [19, 20]. Notably, a recommendation was included in
the first edition of the Merck Manual, which was published
in 1889, suggesting that smoking could be used for the
treatment of bronchitis and asthma [20].
In 1912, the very first cause/eﬀect hypothesis between
lung cancer and tobacco smoking was made in a research
monograph by Adler [20, 21]. In the same year, surgeon
Hugh Morriston Davies carried out the first pulmonary
lobectomy for lung cancer in London. The patient died of
infection 8 days after the operation, due to lack of cavity
draining, a procedure not followed in such cases until 1929.
In 1914, Kellogg stated in a public health report that can-
cer killed 75000 people in the US each year, corresponding to
1 out of 20 deaths, and he noted that domestic animals were
aﬀected by cancer more frequently than humans, probably
because of the indoor pollution deriving from combustions
and tobacco smoking [22].
Almost two decades later, Dr. James Gilmore, a 48-
year-old gynecologist from Pittsburgh, underwent the first
successful left pneumonectomy for carcinoma. The opera-
tion was carried out by Dr. Evarts A. Graham, a pioneer
in thoracic surgery [23–25]. Nearly 25 years later, Graham
would die of the same disease that helped make him
internationally renowned [26, 27].
Before the Second World War, experimental research
on carcinogenesis from tar and polycyclic hydrocarbons
was begun by an Argentinean researcher, Roﬀo [28–30].
Many of his studies were published in German scientific
journals, which sank into oblivion after the war until WHO
finally recognized him as the “forgotten father” of tobacco
carcinogenesis, even though his research had already drawn
the attention of tobacco manufactures in the past [31, 32].
On May 27, 1950, Ernest L. Wynder from the Sloan
Kettering Institute and Evarts A. Graham published the
first scientific paper on tobacco smoking as a possible
etiological factor for bronchogenic carcinoma in JAMA [18].
684 patients with lung cancer were studied, 96.5% of whom
were heavy smokers while carcinoma was very rare (2.0%)
in nonsmokers or light smokers. Wynder also assumed that
3-4 Benzopyrene, which was present in the cigarette smoke
condensate, could cause cancer in humans. This hypothesis
drove him to conduct the first experiments in tobacco smoke
carcinogenesis.
In 1951, Richard Doll and Bradford Hill started the
first extensive prospective epidemiological study, which was
published in British Medical Journal in 1961 and confirmed
the relationship between smoking and lung cancer [33]. The
authors discovered that among the 1357 patients that were
admitted to British hospitals with lung cancer, 99.5% were
smokers.
A year later, Reader’s Digest, which had a large circulation
at the time, featured an article with the provocative title
“Cancer by the Carton,” in which the role of cigarette smoke
in lung cancer was described as “a medical controversy. . .
largely kept from public notice.” [34] The article had an
enormous impact on public opinion, putting pressure on
the tobacco industry (Big Tobacco). As a consequence, on
December 15, 1953, tobacco executivesmet at the Plaza Hotel
in New York in order to create a cartel against the growing
body of scientific evidence linking smoking to lung cancer,
which had started to raise concern and distrust against
tobacco manufacturers. Apart from the secret agreements,
they jointly wrote the “Frank Statement,” which aimed at
contrasting the evidence implicating smoking as a health
issue [35]. This document/press release was published in
more than 400 newspapers on January 4, 1954, reaching
nearly 43 million readers.
A decade later, the first Surgeon General’s report that
addressed the consequences of tobacco smoke for public
health was released [20]. By then, the distribution of free
cigarettes at annual medical and public health meetings had
already stopped.
The second part of the twentieth century saw a rapid
increase in this disease leading to a lung cancer epidemic,
especially in males of the developed countries [36, 37].
In the US, where measures for the control of tobacco
dependency had already been established in the fifties, lung
cancer incidence for men peaked in 1982 and a slow but
steady reduction followed afterwards [38, 39]. Conversely,
in other countries, where antismoking measures were less
aggressive, a similar trend has not been observed and inci-
dence has continued rising in some countries such as Japan
[40–44].
3. What Does the Smoker Smoke?
Even though the carcinogenetic mechanisms of tobacco
smoke are not fully explored [45], only very few smokers
and non-smokers know what they inhale. Tobacco smoke
is a mixture of a corpuscular part (5%) and a gas phase
(95%). The former, without water or nicotine, is constituted
of tar. There are 0.3–3.3 billion particles per milliliter of
cigarette smoke and more than 4000 compounds [46, 47],
including more than 60 agents with at least suﬃcient
evidence of carcinogenicity in laboratory animals and 11
human carcinogens according to the International Agency
for Research on Cancer (IARC) [48, 49].
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Besides well-known organ-specific carcinogenic sub-
stances, such as polycyclic aromatic hydrocarbons, 4-
(methyl-nitrosamino)-1-(3-pyridyl)-1-butanone (NNK),2-
Naphthylaine, 4-aminobiphenyl, arsenic, and chromium,
there is another one, which has recently been involved in the
spy case of Litvinenko: Polonium 210 (Po-210).
4. Chemistry
Polonium, also called “radium F,” was discovered by Marie
and Piere Curie in 1898 and was named after the home
land of Curie-Sklodowska. For the discovery of radium and
polonium Marie Curie received a Nobel Prize in Chemistry
in 1911 [50, 51]. The element was discovered while they
were investigating the cause of pitchblende’s persistent
radioactivity, even after the removal of uranium and radium.
Their work was remarkable, considering the means available
in the late nineteen century and the fact that the element can
be found in uranium ores at about 0.1 mg per ton.
Polonium is a fairly volatile metal, rarely found in nature
in pitchblende containing rocks, and constitutes 2.1×10−4%
of the Earth’s crust [52]. The major resources of pitchblende
are located in Canada, the US, Congo, and South Africa.
Polonium has more than 30 radioisotopes, but Po-210 is the
most dangerous and most frequent naturally occurring one
[53]. This isotope has a half-life of 138.4 days, an eﬀective
biological half-time of 46 days [54], and can be created in
the lab, when Bi-209 is bombarded with neutrons. It is a
high energy α-particle emitter (5.3MeV), but it can also
emit gamma photons with energy 803 keV and emission
probability of nearly 1× 10−5 [55, 56]. It decays to stable Pb-
206, and it has a melting point of 254◦C and a boiling one of
962◦C (for Pb-210 these temperatures are 327.5 and 1740◦C
resp.).
5. Toxicity
Polonium is a highly toxic element, with elevated specific
radioactivity, and is dangerous to handle even in milligram
amounts. The maximum allowable body burden for ingested
Polonium is 1100 Bq, which is equivalent to a particle
weighing only 6.6× 10−6 μg [57].
Alpha rays, which are formed by helium 4 (He-4)
nucleus, are the least penetrating type of radiation and they
manage to travel only a few centimeters in air. They can
be easily stopped by obstacles, such as a sheet of paper,
and they can penetrate living tissues by only a few microns
[55, 58, 59]. In fact, since they lose all of their energy after a
short distance, they can be dangerous for tissues only when
substances emitting alpha particles enter the organism by
respiration or ingestion.
In addition, alpha rays are highly ionizing and, therefore,
are particularly harmful for living tissues. 1 mg of polonium
can emit as many alpha particles as 5 grams of radium.
The impact on humans can be devastating, as it can cause
considerable damage by causing cell death, promoting a
massive, progressive, and rapid necrosis, and not allowing
the organism enough time to replace the quantity of dead
cells [57].
6. Main Applications
Po-210 use is rather limited due to its high alpha radiation
emissions and the diﬃcult extraction process. The main uses
are (a) as a resource of neutrons when it is mixed with
beryllium, (b) as an energy resource for satellites and other
space devices, (c) in antistatic devices of some precision
instruments and in brushes that eliminate dust gathered
on photographic film, and (d) in devices that eliminate
static charges in textile mills, though less dangerous beta-ray
sources are now more widely used [57].
7. From Earth to Tobacco
Traces of Po-210 can be found in many plants and foods and
consequently, in human tissues as well [60, 61]. The principal
resource of natural Po-210 is food. Spencer et al. report that
77.3% of the daily Po-210 intake of an adultmale comes from
food, 4.7% from water, and 0.6% from air. Notably, inhaling
cigarette smoke can supply much more Po-210 (17.4%) than
water and air combined [62]. 50–90% of the ingested Po-
210 will promptly leave the body in feces, but the remaining
fraction enters the blood circulation [63].
The discovery of the presence of Po-210 in tobacco smoke
dates back to the early sixties, thanks to the work of Turner
et al. [60], Marsden and Collins [64], and Radford and Hunt
[65]. In fact, Po-210 and its precursor, lead 210 (Pb-210), are
present in tobacco plants [66], as they may be absorbed in
various associated ways.
(1) Through the plant’s roots, directly from terrain that
contains uranium [67–69].
(2) Coating on leaves as a result of meteorological
events, rain, snow, and environmental dust. In fact,
Radon-222, a product of U-238 decay, is a noble
and volatile gas that can partially escape from
terrain into the atmosphere and create Pb-210 and
Po-210. These are absorbed by atmospheric dust,
creating the Aitken particles that consequently lie
on the leaves. The numerous trichomes of tobacco
plants resemble filamentous pores and are metal
accumulators, particularly of Pb-210 and Po-210.
The quantity of the latter will then increase, as
there is further Pb-210 decay [70, 71]. Fleischer and
Parungo confirmed experimentally that radon and
lead decay products are highly concentrated in the
trichomes of leaves [71]. Additionally, accumulation
mechanisms of Pb-210 on trichomes of tobacco have
been widely discussed and studied by Martell and
Poet [72, 73] while Skwarzec et al. suggested that
this is the principal way Po-210 enters tobacco plants
[68].
(3) On the other hand, the majority of authors, such as
Singh and Nilekani, have identified the importance
of the fertilizers employed [74]. Calcium polyphos-
phates fertilizers are enriched with radium, which
is chemically similar to calcium, and derive from
soil that contains pitchblende and apatite [67, 75].
Interestingly, according to several studies, Indian
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cigarettes, which are made of scarcely fertilized
tobacco, are 6 to 15 times less radioactive compared
to the American ones, which derive from intensively
fertilized plants [74].
8. From Tobacco to Lungs
The journey of Po-210 and Pb-210 towards bronchopul-
monary apparatus starts by lighting a cigarette. In this
combustion chamber, tobacco burns, reaching 800–900◦C
when inhaling, and smoke is created, which is composed
of a corpuscular (5%) and a gas phase (95%) [46]. Po-
210 and Pb-210 are adsorbed in the insoluble particles of
the corpuscular phase [65]. The latter is present in a high
quantity and is a weak alpha (<1×10−5), gamma, beta, and
X emitter. All these inhaled particles are deposited in the
broncho-pulmonary apparatus and particularly in segmental
bronchi bifurcations, due to ciliary action. According to
measurements by Cohen et al., radium and thorium are
also present in cigarettes; however, 99% of the radioactivity
comes from Po-210 [75], which remains in the broncho-
pulmonary apparatus after inhalation [76].
All these particles have a diﬀerent “destiny” based on
the eﬃcacy of the mucous-ciliary clearance. This mechanical
purification is reduced gradually in smokers with COPD,
resulting in the accumulation of insoluble Pb-210 particles,
which decay to Po-210 over time [70, 77]. In fact, the more
severe COPD becomes, the greater the risk of radioactive
load accumulation is [77].
Subsequently, radioactive particles reach various organs
and tissues through pulmonary and systemic circulation and
cause mutations of the genetic cellular structure, deviations
of the standard cellular characteristics, accelerated ageing,
and quicker death due to a wide range of diseases [78,
79]. In smokers, Po-210 levels are in fact significantly
higher in blood (by 30%) [65, 80], urine (6-times higher)
[81], liver, kidney, heart, and psoas muscle [82]. Little and
McGandy estimated that Po-210 concentration in blood is
63.64mBq/kg of blood in smokers and 28.12mBq/kg of
blood in non-smokers [83]. Notably, concentrations of Pb-
210 and Po-210 in rib bones and alveolar lung tissues were
two-times higher in ex-smokers compared to non-smokers,
even a year after smoking cessation [66].
Polonium radiation in the bronchial epithelium depends
not only on the particle concentration of these areas, but also
on the time of their permanence. Half-life of polonium is
138.38 days and of lead 22 years, which decays afterwards
into polonium. There is a significant cancer risk due to
chronic exposure to low levels of insoluble alpha-emitting
particles [84, 85], which are responsible for high radiation
doses in small tissue areas particularly in the bifurcations
(hot spots) [70]. This process is facilitated by the above-
mentioned impaired mucous-ciliary clearance of smokers. In
fact, according to Auerbach et al. [86], metaplastic lesions
are present in the ciliated epithelium of all heavy smokers
[87, 88]. Po-210 of the insoluble particles becomes even
more penetrative because of zones with damaged or scarcely
ciliated epithelium, where mucous mainly stagnates [65, 89].
More and more studies suggest that smokers and ex-smokers
with moderate to severe COPD have a higher incidence of
lung cancer [77, 90–92].
9. Po-210 Quantity in Tobacco Smoke
Po-210 alpha radioactivity in tobacco smoke depends on
several variables: geographic region of tobacco growth,
storage time and modality, presence of a filter, its length and
composition, and the way of smoking [85]. Furthermore, the
associated risk of smoke derives not only from the quantity
and quality of carcinogenic substances, but also from the
scarce eﬃcacy of filters, which fail to reduce their amount
adequately. In fact, common filters, found in the cigarettes
of commerce, are able to reduce Po-210 activity on average
by 4.6% [93]. There is evidence that resin filters may reduce
lung exposure to alpha radiation even more [94].
Radford and Hunt [65] and Mussalo-Rauhamaa and
Jaakkola [95] reported that about 6.5% to 22% of the Po-
201 contained in cigarettes was found in mainstream smoke.
Other authors stated diﬀerent percentages, ranging from
3.7% to 58% [96]. According to Parfenov, approximately
50% of a cigarette’s Po-210 is transferred with the smoke,
35% remains in the stub, and 15% is found in the ash [97].
Professor Gattavecchia from the Complex Unit of the
Institute of Chemical, Radiochemical, and Metallurgic Sci-
ences of University of Bologna (SMETEC), in association
with ENEA (Italian National Agency for New Technologies,
Energy, and Sustainable Economic Development) and the
Italian Society of Tobaccology (SITAB), have conducted var-
ious studies on the alpha radioactivity of Po-210 in tobacco
smoke. It has been confirmed that a cigarette with tobacco of
Western origin emits 75mBq of alpha radioactivity from Po-
210, distributed in mainstream (5mBq, 6.7%), sidestream
(1.2mBq, 1.6%), and ash (68.8mBq, 91.7%) [97–100].
10. Po-210 and Second-Hand Smoking
Many studies have already reported that second-hand smoke
is an important risk factor for lung cancer. After studying
91540 people for 14 years, in 1981 Hirayama demonstrated
the lung cancer mortality of non-smoker wives or husbands
was one-third higher compared to those with non-smoker
partners [101].
This increased risk was also confirmed by a vast analysis
of two case-control studies conducted in the US and
Europe, in which a dose-response relationship between
lung cancer risk and prolonged exposure to second-hand
smoking has been found among partners, in workplaces
and in public places. Risk for one-oﬀ exposure to spousal
smoking increased by 18% (95% CI= 1–37%) and for
long-term exposure by 23% (95% CI= 1–51%). Augmented
risk for long-term exposure was also found for the work
place (OR= 1.25; 95% CI= 1.03–1.51) and public places
(OR= 1.26; 95% CI= 1.01–1.58) [102].
It should be considered that passive smokers are exposed
to the same components as active smokers, including
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radioactive elements. As a matter of fact, Po-210 in second-
hand smoke is 50–70% the quantity found in active smoke.
Moreover, passive smokers are exposed to environmental
pollution from radon, as well as from Po-210 of cigarette
smoke, both of which increase lung cancer risk [87, 103, 104].
11. Po-210 and Narghil Smoke
Po-210 is also present in narghile´ smoke. An international
multidisciplinary team (from Egypt, Arabia, and France),
coordinated by Khater et al., has recently published a
pioneering study on narghile´ (shisha, hookah) tobacco
radioactivity [105]. Before this research, only very few data
were available on this issue [106, 107].
The research was based on the measurement of some nat-
ural radionuclides activity and the estimation of the internal
radiation dose due to narghile tobamel (moassel) smoking.
Tobamel is a fashionable flavoured tobacco-molasses mixture
(with added glycerol) currently used in narghile´. However,
there are other forms such as jurak, similar to tobamel,
but unflavoured, containing minced fruits and no glycerol
[105]. It is also much stronger in nicotine. The results of
the study revealed a wide range of radioactivity concen-
trations (in Bq/kg dry weight): U-238= 55 Bq (19–93), Th-
234= 11 Bq (3–23), Ra-226 = 3 (1.2–8), Pb-210 = 14Bq (3–
29), Po-210 = 13Bq (7–32), Th-232 = 7Bq (4–10), and K-
40= 719 Bq (437–1044). The researchers concluded that the
average concentrations of natural radionuclides in moassel
tobacco pastes were comparable to their concentration in
Greek cigarettes and tobacco leaves, and lower than that of
Brazilian tobacco leaves [105].
Another recent study on the radioactivity of Greek
tobacco leaves used for cigarettes showed that the annual
eﬀective dose due to inhalation by adult smokers varied
from 42.5 to 178.6 μSv/y (average 79.7 μSv/y) for Ra226;
19.3 to 116.0 μSv/y (average 67.1 μSv/y) for Ra-228; 47.0 to
134.9 μSv/y (average 104.7 μSv/y) for Pb-210. In sum, the
order of magnitude was the same for each radionuclide.
The sum of eﬀective doses of the three radionuclides varied
from 151.9 to 401.3 μSv/y (average 251.5 μSv/y). Notably, the
annual eﬀective dose from Cs137 of Chernobyl origin was
three orders of magnitude lower as it varied from 70.4 to
410.4 nSv/y (average 199.3 nSv/y) [108].
The results of Khater et al., found that the radioactivity
concentration in tobacco products basically depends on the
tobacco content itself, not on other ingredients such as
molasses, glycerol, or fruits. Interestingly, the lower yield of
Po-210 in jurak might be in relation with the Indian origin of
this smoking paste. The reason might be that Po-210 alpha-
radioactivity of Indian tobacco would be several times lower
than that of Western tobacco [74].
12. Po-210 Carcinogenicity in Tobacco Smoke
Eighty-five to ninety out of a hundred lung cancers are
caused by tobacco smoke; nevertheless, less than 20% of
smokers get lung cancer [7]. If individuals contracting
cancer on exposure to cigarette smoke are identified, the
information can certainly be incorporated into eﬀective
prevention strategies [109].
Many factors could influence individual susceptibility to
lung cancer in smokers. Polonium is among them, albeit
it is still less considered or even ignored as a carcinogenic
substance, which is also due to years of concealing by tobacco
manufacturers [110]. As a matter of fact, when associ-
ated to other mutagenic and carcinogenic nonradioactive
substances, which are inhaled with tobacco smoke (such
as aromatic hydrocarbons, cadmium, and N-nitrosamine)
[111], it seems to constitute the principal etiological factor
for lung cancer [112], as long-term tissue exposure to alpha
radiation can induce cancer either by itself or in association
with other non-radioactive carcinogenic substances.
Polonium 210 emits alpha particles, which have a
penetration limit of about 40 microns or less in animal
tissue, but a very high damaging eﬀect [55, 58, 59]. Since the
late nineties, IARC has identified Po-210 as a carcinogenic
element for laboratory animals, classifying it among the
Group 1 agents [49].
DNA chromosome damage by exposure to alpha radia-
tion is 100-times greater than the one caused by other types
of radiation [113]. Little and Radford estimated that the
radiation dose of the bronchial epithelium of bifurcations in
the inferior lobes of people smoking for 25 years would be
2 Sv [114]. This can be explained by the local accumulation
of Pb-210 insoluble particles [72]. According to Martell, the
cumulative dose of alpha radiation in bronchial bifurcations
of smokers that die of lung cancer is approximately 16 Sv
(80 rad). This dose is suﬃcient to induce a malignant
transformation caused by alpha-particles interaction with
basal cells [115, 116].
Black and Bretthauer reported that Po-210 radiation dose
in heavy smokers was up to 82.5mrad (0.83mSv) per day
[117]. Radford and Hunt, estimated that the radiation dose
for a person smoking two packs of cigarettes a day may be
up to 0.4 Sv a year or 10 Sv over a 25-year period [65]. Such
a radiation exposure dose rate was about 150-times higher
than the approximately 0.05 Sv per 25 years received from
natural background radiation sources.
Many lung cancers are adenocarcinomas, a type of lung
cancer that Po-210 inhalation can induce in laboratory ani-
mals [116]. Kennedy et al., induced lung cancer in hamsters,
histologically similar to bronchoalveolar carcinomas (BAC)
of humans, after Po-210 intratracheal instillation [118].
They also implicated the bronchiolar cell of Clara as the
origin of these tumors. Moreover, according toMarmorstein,
adenocarcinomas could be induced with as little as 15 rad of
radioactive polonium, corresponding to one-fifth of the dose
inhaled by smokers of two packets per day over a 25-year
period [113].
Boﬀetta et al. recently reviewed seven case-control studies
and estimated that the odds ratio of BAC for smoking at all
was 2.47 (95% CI= 2.08–2.93). The authors also reported
that the risk increased linearly with duration, amount,
and cumulative cigarette smoking and persisted long after
smoking cessation [119].
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12.1. Mechanism of Action. In a recent study, Prueitt et al.
tried to explain the way alpha radiations aﬀect DNA [120].
Ionizing radiation, including Po-210, could silence the tumor
suppressor gene p16(INK4a) by promoter methylation.
Inactivation of this gene was found in lung cancers of
both smokers and radiation-exposed non-smoker workers.
The authors concluded that such inactivation was shown
to play a major role in carcinogenesis, but further studies
could demonstrate the level of this role compared to other
carcinogenic substances.
12.2. Biological Harm. But what is the level of biological
damage caused by tobacco smoke Po-210? Estimating the
damage is a very diﬃcult and complicated task. Using the
1990 ENEA data on the average time of Po-210 presence
in lungs, which is 53 days [121], the data of the BEIR IV
Committee on lung cancer risk after exposure to radon and
its decay products (Pb-210, Po-210) [122], and the data of
the International Commission on Radiological Protection
(ICRP), which are based on the survivors of the bomb A of
Hiroshima [123], it is possible to estimate the lung cancer
risk, which is 4 × 10−4 year−1 (4 cases per 10000 smokers
per year, which corresponds to nearly 5000 cases for the
11.1 million Italian smokers). This estimate does not take
into account the promoter role of Po-210 (cocarcinogen) in
the bronchopulmonary cancer and the overall carcinogenic
activity of all substances [124].
To render the biological harm deriving from Po-210 in
smoke more comprehensible, it has been compared to the
damage caused by radiation in conventional chest X-rays.
Since the dose of a modern chest radiograph is 0.034mSv
[125, 126], a smoker of 20 cigarettes per day receives a
radiation dose of 0.08–0.09 Sv equivalent to approximately
300 chest X-rays per year [98, 99, 113, 127]. However,
the alpha radioactivity alone does not cause the steep
rise of the carcinogenic risk; instead, it is the combined
and multiplicative action of each carcinogenic and co-
carcinogenic component responsible for such consequence
[88, 111, 128].
13. A Histotype Shift
There is evidence that in the last 40 years a histotype change
of lung cancers has been noticed, shifting from squamous
cell carcinoma to adenocarcinoma, in which the bronchial-
alveolar (BAC) subtype is also included [129]. The above-
mentioned shift was observed in the early seventies and has
been noted ever since in the US [130, 131] and Europe [132].
The factors that have induced this shift are various and
perhaps not all known. Nevertheless, almost all of them are
linked to the tobacco cultivation and cigarette manufacture
changes since the fifties. The most common are as follows.
(a) The utilization of diﬀerent varieties of tobacco in the
US cigarette blends. This change reduced benzopy-
renes in smoke, but produced an increase of nearly
50% in nicotine-derived nitrosaminoketone (NNK)
in the last quarter of the twentieth century [133, 134].
(b) The introduction of low-tar, low-nicotine, filtered
cigarettes since the mid fifties, which seems to have
contributed to the overall decline in lung cancer
and the upward trend in the incidence of adeno-
carcinoma [135–138]. Some studies demonstrated
a decline in lung cancer risk in smokers of filter
cigarettes [139]. Even the common filters made of
cellulose acetate have contributed to the aforemen-
tioned histotype change [140], nevertheless, smokers
frequently breath in these cigarettes more deeply and
as a result, a greater quantity of carcinogens is trans-
ported more distally, towards the smaller bronchial
airways, where adenocarcinomas often arise [141,
142]. In addition, the increased consumption of
filtered cigarettes has also reduced the yield of car-
cinogenic polycyclic aromatic hydrocarbons (PAHs),
which are inducers of squamous cell carcinomas,
simultaneously increasing the carcinogenic tobacco-
specific N-nitrosamines (TSNAs), which are inducers
of adenocarcinomas [137, 143].
Interestingly, in the fifties the race for the safer filter
led to a severely dangerous incident. Lorillard pro-
duced 13 billion cigarettes from 1952 through 1956
based on a filter composed of asbestos and cotton
fibers. Each filter contained 10mg of crocidolite, the
fibers of which could be found in the mainstream
smoke from the first two puﬀs. Consequently, a
person smoking a 20-cigarette pack each day could
inhale more than 131 million crocidolite fibers,
which were longer than 5 μm, in a year’s time [144].
When proof of the danger of asbestos started to
surface, these cigarettes were called in, after spreading
harmful fibers to the lungs of thousands of smokers.
(c) The massive introduction of polyphosphate fertilizers
in tobacco cultivations, contributing alpha radiation
(from Pb-210 and Po-210) and TSNAs significantly
[48], especially in Western cigarettes rather than in
the ones from poor agricultural areas like India.
Studies showed that American tobacco is 5.5-times
more radioactive compared to the Indian-grown one
(19.09mBq/g versus 3.33mBq/g resp.), due to the
polyphosphate fertilizers [74, 145]. Because of the
lower radioactivity, the prevailing type of lung cancer
histotype in India is the squamous cell carcinoma and
the cell type patterns have remained unchanged vir-
tually since the early sixties [146]. As a matter of fact,
in 1962, Viswanathan et al. reported 50.5% squamous
cell carcinomas versus 28.4% adenocarcinomas [147]
while more recent studies reported 58–67% versus
10–19%, respectively, [148–150].
14. How to Reduce the Radioactive Load of
Tobacco Smoke?
Regulating and reducing this harmful radiation, which
comes from fertilizers, could help reduce lung cancer inci-
dence [151]. Tobacco radiation could be reduced by applying
various solutions, which may also work combined.
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(a) Use of alternative polyphosphate sources, such as
organic fertilizers from animals [151].
(b) Use of ammonium phosphate as a fertilizer, instead
of calcium phosphate [151].
(c) Diﬀerent storage methods. A study proved that Po-
210 radioactivity of tobacco rose over time while in
storage [152]. As a consequence, harvesting tobacco
while it is still green and avoiding prolonged storage
in silos in order to prevent an increase in Po-210
concentration due to Pb-210 slow decay could be
recommended.
(d) Genetic modifications of tobacco plants with signif-
icant reduction of trichomes concentration on the
leaves, on which Pb-210 and Po-210 accumulate [71].
(e) Resin filters may decrease lung exposure to alpha
radiation [94]. On the contrary, common filters
reduce Po-210 activity, on average, by 4.6% [93].
(f) LaRock et al. recommended a biological way to
remove Po-210 by treating polyphosphate rocks with
bacteria capable of reducing sulphates [153].
(g) Perhaps the simplest and most applicable solutions
would be the quantitative decrease in polyphosphates
use in tobacco cultivations and the regulation of
the maximum acceptable level of alpha radiation of
cigarettes, which should also be clearly indicated on
the packet [110].
15. Big Tobacco Has Been Aware but Kept Quiet
While multinational tobaccomanufacturers have been aware
of the alpha-radioactivity presence in tobacco smoke since
the sixties, they have covered it up strategically. Not by
chance, the polonium dossier was symbolically entitled
“waking a sleeping giant” [110].
Among the 37 million documents that were released
through the site www.pmdocs.com, one can find the lawsuit
of the State ofMinnesota against Philip Morris Incorporated,
et al., in which there are 481 confidential documents and
memorandums on the alpha-radioactivity from Po-210 in
tobacco smoke (still available on 1 January 2011). The
archives bring out the fact that Philip Morris has been aware
of the lead and polonium existence in cigarettes since the
sixties [154], as was also proved from studies by Turner et
al. 1958 [60], Radford and Hunt (1964) [65], and recently
by researchers from Mayo Clinic [110]. In these internal
documents, it can be seen that there was a clear interest
in polonium’s radioactivity and the induction of bron-
chogenic carcinomas in laboratory animals and presumably
in humans [155]. In fact, there was a recommendation to
avoid any public attention to the problem for fear of “waking
a sleeping giant” [110].
In 1980, one confidential memorandum revealed that
the issue was mainly caused by calcium phosphates fertil-
izers employed in tobacco cultivations. Moreover, cigarette
manufacturers knew about the studies conducted by Martell
[72], regarding the possibility of decreasing tobacco and
smoke radioactivity by using ammonium phosphate instead
of calcium phosphate as fertilizer. Nevertheless, this recom-
mendation was considered to be “an expensive point” [152].
So far, the majority of public opinion still ignores the
presence of polonium radioactivity in tobacco smoke and
the serious public health threat that it represents. Yet, from
a communicative and motivational point of view, it could
become a great opportunity for prevention and smoking
cessation. For now, it seems that something has changed
in the media and scientific world since the widely covered
Litvinenko case and the paper of Muggli et al. [110]. In
fact, the authors of the aforementioned study and the Italian
Tobaccology Society have already requested the placement of
a clear indication about the radioactivity content on cigarette
packets.
16. Conclusions
Polonium-210 represents one of the principal causes of
lung cancer and its shift from squamous cell carcinoma
to adenocarcinoma. Provided that it is true that tobacco
manufacturers have been aware of the presence of Po-210
in smoke since the early sixties and concealed its existence
intentionally in various ways, it is likely that the medical and
scientific sector is guilty of having ignored it.
It is necessary that the medical and scientific world
becomes aware and conscious of this problem, creating
systematic educational programs of tobaccology in the
university curricula of the medical sciences courses. Like-
wise, governments should force manufacturers to introduce
cigarettes with low Po-210 concentration and place a clear
indication about this on the packet in order to reduce
smokers’ risk.
Finally, since people fear everything that is radioactive,
perhaps it would be useful to create an adequate information
campaign so as to enable and accelerate smokers’ motiva-
tional pathways and increase the eﬃcacy of anti-smoking
programs [156].
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